Same-day hepatitis C treatment moves from concept to field testing in three countries

A multinational protocol is putting hepatitis C care under a direct operational test in Armenia, Georgia and Tanzania. The CUTTS HepC study is examining whether a same-day test-and-treat pathway built around a rapid point-of-care antibody result can be delivered safely and feasibly for people who inject drugs, a population that carries a disproportionate share of the global infection burden.

The rationale is straightforward. Hepatitis C remains curable, yet diagnosis and treatment coverage continue to lag far behind need, especially in low- and middle-income countries where most people living with the infection reside. In 2022, an estimated 50 million people were living with hepatitis C worldwide, with 1 million new infections each year. For people who inject drugs, delays in testing, loss to follow-up, and fragmented clinic pathways can be enough to prevent cure even when direct-acting antiviral therapy is available.

Two simplified care pathways under direct comparison

The study uses a multi-country, non-randomised, quasi-experimental, prospective comparative two-arm design. Arm 1 follows a standard simplified test-and-treat pathway aligned with global guidance. Arm 2 tests a more aggressive model: rapid, same-day treatment initiation using a presumptive treatment approach after shortened read-time of the point-of-care OraQuick hepatitis C antibody test.

This is not a laboratory exercise. It is an implementation question with immediate consequences for clinic flow, patient retention, and cost. If a person can be moved from diagnosis to treatment in one encounter, the window for disengagement shrinks sharply. For a hard-to-reach population, that logistical change can matter as much as the antiviral regimen itself.

The protocol makes retention in care a central endpoint because cure depends on more than medication access. Even highly effective treatment will fail at a population level if patients never return after screening, if confirmatory testing adds friction, or if multiple visits create opportunities for dropout. The study also includes cost-effectiveness outcomes, reflecting the reality that simplification must work clinically and economically if it is to scale.

Why an antibody-only shortcut is being tested

The operational attraction of the rapid antibody approach is obvious: it may compress the diagnostic pathway and reduce waiting time before treatment begins. That matters in settings where laboratory infrastructure is limited, transport to referral sites is difficult, or patients are unlikely to return for additional visits. The biological logic is less about changing the virus than changing the system around it. Hepatitis C transmission persists when care is slow, and cure rates at the individual level do little if the care cascade leaks at the front end.

The protocol also evaluates the accuracy of the OraQuick antibody test in predicting viraemia. That question sits at the center of the entire strategy. Antibody detection confirms exposure, not necessarily active infection, so a same-day presumptive treatment model depends on how well that simplified signal maps onto true viraemic disease in the enrolled populations. If the test performs well enough in context, it could support a one-step or near-one-step pathway. If not, the model may still prove useful as a triage tool, but not as a universal gateway to treatment.

People who inject drugs are the focus for a reason

Eligibility is limited to treatment-naïve adults aged over 18 years who inject drugs in Armenia, Georgia and Tanzania. That choice is clinically and epidemiologically coherent. People who inject drugs are disproportionately affected by hepatitis C, and they often face overlapping barriers that make conventional models especially brittle: unstable access to care, stigma, competing priorities, and repeated exposure to settings that do not accommodate prolonged diagnostic sequences.

A same-day model may be particularly relevant in this group because it reduces the number of moments when care can fail. One brief encounter can replace a chain of referrals, laboratory waits and return appointments. In practical terms, that can determine whether a patient starts curative therapy or disappears from the care cascade before a prescription is ever written.

Recruitment began in October 2024 in Armenia, June 2025 in Georgia and August 2025 in Tanzania, with enrollment expected to close by December 2026. The staggered start dates suggest a phased rollout across very different health system settings, which should strengthen the implementation relevance of the findings. Even so, the non-randomised design means interpretation will have to remain anchored to the realities of comparative implementation rather than efficacy alone.

Ethical review and dissemination are built into the protocol

The trial has been reviewed by the WHO Ethics Review Committee, the Alfred Hospital Ethics Committee in Australia, and local ethics committees in each participating country. Dissemination plans extend beyond journals and conference presentations. Summary reports and workshops with key stakeholders and communities affected by hepatitis C are planned through relevant organisations and networks, including the global Community Advisory Board.

That approach matters because implementation studies in marginalized populations can fail in a familiar way: they produce evidence without building trust. Here, the dissemination plan signals an effort to return results to the communities most likely to be affected by the eventual care model. For a service-delivery trial involving people who inject drugs, community engagement is not peripheral. It is part of the intervention environment.

What the trial could change if the model holds up

The protocol is designed to inform national scale-up of simplified care models in the three participating countries, while also informing possible next steps toward even leaner diagnostic pathways. The most consequential possibility is a future in which one-step diagnostic workflows and same-day treatment become realistic in selected scenarios, rather than aspirational in policy documents.

If the rapid antibody-based pathway achieves acceptable feasibility, retention, and cost-effectiveness, health systems may have a practical template for bringing cure closer to the point of first contact. If the model underperforms, the trial will still define where simplification stops working, whether because of test limitations, patient preferences, or system constraints. Those distinctions will shape how far hepatitis C programs can safely move away from multi-visit pathways without sacrificing accuracy or continuity of care.

Trial registration: NCT06159504.


Reporting by Dr. A. Nikhil Krishnan, MBBS for Medicine World Foundation, with additional data provided by BMJ Open.